Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | HPGD | P15428 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | SNCA | P37840 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3688297 | 1.00 | KDM4E (0.77) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL3690896 | 0.94 | KDM4E (0.80) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL3690899 | 0.94 | KDM4E (0.80) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL30966315 | 0.94 | KDM4E (0.80) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL7247313 | 0.92 | KDM4E (0.84) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4623922 | 0.92 | KDM4E (0.84) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL30739528 | 0.92 | KDM4E (0.84) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL13168878 | 0.90 | KDM4E (0.79) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL25306695 | 0.89 | KDM4E (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL7966747 | 0.89 | KDM4E (0.74) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| US-4337270-A | ANTIALLERGENS; ANTIANAPHYLACTIC AGENTS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1982-06-29 | — | — | US | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | KDM4E 3045/4885ALDH1A1 626/4885HPGD 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.